Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business
June 13, 2022 08:05 ET
|
Avid Bioservices, Inc
New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost...
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
March 16, 2022 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
March 01, 2022 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
January 10, 2022 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
December 07, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
October 07, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments
September 08, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter...
Avid Bioservices to Participate at Upcoming Investor Conferences
September 02, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
July 01, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
June 29, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed...